Login / Register for free to get access to My MedWorm

LexisNexis® Mealey's™ Baycol Legal NewsLexisNexis® Mealey's™ Baycol Legal News RSS feedThis is an RSS file. You can use it to subscribe to this data in your favourite RSS reader, such as GoogleReader, or to display this data on your own website or blog. subscribe with MyMedWormSubscribe to this data using MyMedWorm.subscribe with GoogleReaderSubscribe to this data using GoogleReader.subscribe with BloglinesSubscribe to this data using Bloglines.subscribe with MyYahooSubscribe to this data using MyYahoo.

This page shows you the latest items in this publication.

94 records returned

Magistrate Appointed To Oversee Endgame Process In MDLemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation judge at a Nov. 8 status conference appointed Magistrate Judge Susan Richard Nelson chair of a committee to establish and oversee the "endgame" process and eventual termination of the litigation (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Bayer Wants Putative Class Dismissed For Discovery Violationsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. in a Nov. 9 motion moved for dismissal of a putative consumer class action, arguing that the representative plaintiffs have violated court order by failing to provide their case-specific experts for deposition (In Re: Baycol Products Litigation, MDL No. 1431; Joseph R. Elich v. Bayer Corp., et al., No. 02-0434; Loren Kofsky v. Bayer Corp., et al., No. 02-0141, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Plaintiff Argues Case Should Be Sent To Mediationemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation judge on Nov. 28 is allowing the representatives of the estate of a woman who died after filing her Baycol rhabdomyolysis case an extension to respond to a pending motion to dismiss by Bayer (Rosalind Fryberg v. Bayer Corp., et al., No. 02-3055, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Pro Se Plaintiff Seeks Compensation To Appear As His Own Expertemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this article1 CommentDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. in a Dec. 4 motion seeks an order compelling a pro se plaintiff, who wishes to produce himself as an expert witness in his case, to appear for deposition without receiving compensation (Edward Ronwin v. Bayer Corp., et al., No. 02-0200, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Plaintiffs' Counsel Says Fee Penalty Request Excessiveemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The law firm representing a Baycol multidistrict litigation plaintiff is opposing a request for fees by the defendants against it for a deposition at which the plaintiff did not appear, arguing that the requested amount is excessive (Curtis Coates, et al. v. Bayer Corp., et al., No. 03-1175, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Plaintiffs With Delinquent Discovery Identified In Ordersemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Baycol multidistrict litigation Judge Michael J. Davis on Dec. 5 and 19 issued two orders listing plaintiffs whose discovery requirements are delinquent and are facing dismissal with prejudice (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Woman Says Husband's Death Caused By Heart Drug Plavixemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
TRENTON, N.J. - The wife of a man who allegedly died from subdural hematoma caused by Bristol-Myers Squibb's Plavix heart drug sued the manufacturer in a federal court on Dec. 15 (Eloise LaBarre, et al. v. Bristol-Myers Squibb Co., et al., No. 06-CV-06050, D. N.J.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Baycol MDL Parties Report On Status Of Litigationemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - According to a joint status report filed in the Baycol multidistrict litigation before the U.S. District Court for the District of Minnesota on Nov. 7, there are 2,195 cases active, down from 14,807 at the height of the litigation (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Baycol Plaintiff Files Motion For Dissolution Of MDLemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation judge on Nov. 6 denied a plaintiff's motion for expedited hearing on his motion for remand because of his failing health; the plaintiff was also moving for dissolution of the MDL, arguing that the court has met its goal of conducting common discovery and that remand of all cases was appropriate (Joseph Landrieu v. Bayer Corp., No. 01-MD-01431-MJD; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Defendants Oppose Withdrawal Of Branch Law Firm From 141 Casesemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In a Nov. 6 brief, Bayer Corp. and GlaxoSmithKline (GSK) are opposing motions by The Branch Law Firm to withdraw as counsel for 141 plaintiffs before the Baycol multidistrict litigation court, arguing that the court has stated it would not stand for attorneys "cutting and running from their obligations to clients" (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Counsel Reaches Impasse With Plaintiff, Withdrawsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this article1 CommentDiscuss or comment on this article.
MINNEAPOLIS - A motion by the law firm of Zimmerman Reed to withdraw as counsel due to an "impasse" with the plaintiff in a Baycol case was granted by multidistrict litigation Judge Michael J. Davis on Nov. 6 (Darlene Murphy, et al. v. Bayer AG, et al., No. 05-1728; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Consumer Class Representative Says Criteria For Remand Are Completeemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - A putative Baycol consumer class representative on Nov. 1 filed for remand from the Baycol multidistrict litigation court, arguing that he has completed the criteria established by the court for remand eligibility (George F. McCollins, et al. v. Bayer Corp., et al., No. 02-CV-199; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

GSK Says Role In Litigation Limitedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - According to a recently released transcript from a Sept. 25 hearing on a Baycol plaintiff's motion to compel, counsel for GlaxoSmithKline (GSK) stated that the company's role in the overall litigation has been extremely limited (Edna Dempsey v. Bayer AG, et al., No. 03-1097; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See Oct. 2006, Page 4). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Amiodarone Heart Drug Case Remanded To State Court On Court's Sua Sponte Motionemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
NEW ORLEANS - Acting on a jurisdiction issue it raised sua sponte, a Louisiana federal court on Sept. 8 ruled that a generic Cordarone case was improperly removed on the basis of the federal officer defense, federal question and a fraudulently joined pharmacist (Howard Stanley, et al. v. Wyeth Inc., et al., No. 06-1979, E.D. La.; 2006 U.S. Dist. LEXIS 64037). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

3 Heart Device Cases Remanded For Amounts, Sales Rep Liabilityemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
Two federal courts recently remanded three heart device cases to state court after finding no evidence that two plaintiffs sought more than the $75,000 federal jurisdictional threshold and that there is a colorable claim against a sales representative (Coleman S. Smith v. Medtronic Sofamor Danek, USA, Inc., No. 06-1992, D. S.C., Beaufort Div., 2006 U.S. Dist. LEXIS 53225; Charles Ogden v. Medtronic Sofamor Danek, USA, Inc., No. 06-1994, D. S.C., 2006 U.S. Dist. LEXIS 52223; Rodolfo Baeza, et al. v. Larry Tibbetts, et al., No. 06-407, D. N.M.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

U.S. Supreme Court Signals It May Take Up Preemption Of PMA Devices Againemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
WASHINGTON, D.C. - The U.S. Supreme Court on Nov. 6 signaled that it may take another look at whether premarket approval (PMA) medical device claims are preempted by federal law when it invited the U.S. solicitor general to file a brief about the government's current view on the subject (Charles R. Riegel, et al. v. Medtronic, Inc., No. 06-179, U.S. Sup.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Request For GSK Personnel Files Deniedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol federal multidistrict litigation judge on Sept. 29 denied a request by a plaintiff to compel GlaxoSmithKline (GSK) to produce personnel files, ruling that the plaintiff has failed to show a need for them at this time (Edna Dempsey v. Bayer AG, et al., No. 03-1097; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Bayer Says Case-Specific Opinions Should Be Excluded As Genericemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In a Sept. 26 motion, Bayer is seeking exclusion of an expert report submitted in a putative no-injury class action, arguing that it contains generic opinions and was submitted after the deadline for generic expert reports (Michael E. Black, et al. v. Bayer Corp., et al., No. 02-0199, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Pro Se Litigant Moves For Sanctions After 2-Day Depositionemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - A pro se litigant in the Baycol multidistrict litigation on Oct. 20 moved for sanctions against Bayer Corp., saying that the stress of a two-day deposition caused him to suffer a dangerous irregular heartbeat (Michael and Meryle Fisher v. Bayer Corp., No. 03-2894; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See September 2006, Page 7). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Defendant Medical Clinic Dismissed Pursuant To Remand Orderemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - On July 6, the Baycol multidistrict litigation judge dismissed a Mississippi medical clinic that argued that a prior remand order found that the plaintiff failed to allege cause of action against it (Luella Beasley, et al. v. Bayer Corp., et al., No. 03-4954, D. Minn.; In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See May 2006, Page 8). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

More Than 800 Plaintiffs Could Face Dismissals For Delinquent Discoveryemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Baycol multidistrict litigation Judge Michael J. Davis on Oct. 18 issued two orders listing plaintiffs whose discovery requirements are delinquent and are facing dismissal with prejudice (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

10th Circuit: Remand Not In Error For Crestor Plaintiffemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
DENVER - A district court did not err in granting remand to a man allegedly injured by the cholesterol drug Crestor because it properly determined the possibility of success of his claims against a non-diverse defendant at the time of removal, a 10th Circuit U.S. Court of Appeals panel ruled Oct. 11 (Ron Nerad v. AstraZeneca Pharmaceuticals, LP, et al., No. 05-6128, 10th Cir.; See October 2005, Page 5). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Bayer Suspends 2, Hires Independent Counsel For Trasylol Study Investigationemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
LEVERKUSEN, Germany - Bayer Corp. on Oct. 13 announced that it has suspended two unidentified people in connection with the withholding of a company study that showed that Trasylol may increase the risk of death, serious kidney injury, congestive heart failure and strokes. Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Ex-FDA Head Crawford Pleads Guilty To Failing To Disclose Stock Holdingsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
WASHINGTON, D.C. - Former Food and Drug Administration Commissioner Lester M. Crawford on Oct. 17 pleaded guilty to two federal misdemeanor counts of failing to disclose that he and his wife owned stock in companies regulated by the FDA (United States of America v. Lester M. Crawford, No. 06-438, D. D.C.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

Preemption Denied Where New Drug Warnings Weren't Considered By FDAemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
PHILADELPHIA - A Pennsylvania federal judge on Oct. 16 declined to give deference to the Food and Drug Administration's preemption rule and said a failure-to-warn claim in an Elidel case is not preempted where the FDA never considered and rejected stronger warnings (Andrea Perry, et al. v. Novartis Pharmaceuticals Corp., et al., No. 05-5350, E.D. Pa.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - January 21, 2007 Category: Medical Law Source Type: info

U.K. Lipobay Plaintiff Allowed To Retain Case In U.S. State Courtemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
WATERBURY, Conn. - The difficulty a U.K. plaintiff may experience in bringing his Lipobay (marketed as Baycol in the United States) case in his home country, as well as the availability of proof in this country, tips the scale in favor of retaining his case in the United States, a state court judge ruled July 25 in response to a forum non conveniens motion by Bayer Corp. (Michael Lake, et ux v. Bayer Corp., et al., D.N. X10 UWY CV 05 5001416 S, Conn. Super., Waterbury Dist.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Says Adverse Event Reports Unverified, Unreliableemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. and GlaxoSmithKline Inc. (GSK) argue in an Aug. 11 brief that the Baycol multidistrict litigation plaintiffs have failed to meet their burden of proving that Food and Drug Administration adverse event reports (AERs) constitute sufficient facts to support their experts' opinions (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See April 2006, Page 4). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Says Experts Should Not Be Permitted To Recite Farquhar Reportemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The defendants in the Baycol multidistrict litigation in an Aug. 11 brief argue that the plaintiffs' witnesses should not be allowed to "parrot" the testimony of witness John Farquhar, M.D., because that testimony was not peer-reviewed and was created solely for use in the litigation (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See April 2006, Page 5). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer: Farquhar Should Not Be Admitted Based On Testimony In Vioxx, Diet Drugsemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In a reply Daubert brief filed before the Baycol multidistrict litigation court on Aug. 14, Bayer Corp. argues that, contrary to the arguments of the plaintiffs, because the testimony of expert John Farquhar, M.D., was ruled reliable in other litigations, he should not be automatically ruled as reliable in the Baycol litigation (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See July 2006, Page 5). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Accuses Plaintiffs' Expert Of Manipulating Epidemiological Dataemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. argues before the Baycol multidistrict litigation in an Aug. 11 reply Daubert brief that plaintiffs' expert Dr. Harland Austin manipulated the data of an epidemiological study to reach the conclusion that Baycol is the most toxic statin (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See April 2006, Page 12). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Boult Has No Support For Persistent Injury Opinion, Bayer Saysemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In an Aug. 11 motion before the Baycol multidistrict litigation court, Bayer Corp. says it wants the opinions of plaintiffs' expert Dr. Charles Boult excluded under Daubert because he has no scientific support for his opinion that Baycol can cause persistent muscle injury (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See July 2006, Page 7). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Says Expert Used Ipse Dixit To Fill In Gaps in Dataemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In an Aug. 11 reply Daubert brief, Bayer Corp. tells the Baycol multidistrict court that the testimony of plaintiffs' expert Dr. Thomas Zizic is unreliable under Daubert because it relies on the ipse dixit of the witness to fill in gaps between his sources and his conclusions (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See July 2006, Page 13). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Wants Experts' Speculation On Ethics Excludedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. is arguing before the Baycol multidistrict court in an Aug. 11 brief that speculations by two plaintiffs' experts, Drs. Stephen Raskin and Richard Kapit, about Bayer's motives in its marketing of Baycol is inadmissible under Daubert (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See July 2006, Page 8). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Opposes Testimony On Baycol As 'Most Toxic' Statinemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In its Aug. 11 Daubert reply briefs, Bayer says that the opinions of two plaintiff experts, Drs. David Richman and Martyn Smith, that Baycol was the most toxic statin, are unreliable and should be excluded under Daubert (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Opposes Testimony That Baycol Causes Long-Term Muscle Injuryemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer says in its Aug. 11 reply brief in support of its motion to exclude the testimony of a physical rehabilitation specialist that there is no scientific support for his view that a patient can have permanent or persistent muscle injury from Baycol that is not signaled by elevated creatine kinase levels (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - August 25, 2006 Category: Medical Law Source Type: info

Bayer Did Not Plead Sufficient Evidence To Prove Prejudicial Forumemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
JACKSON, Miss. - A trial court did not err in finding that Bayer Corp. failed to present sufficient evidence to show that it would be unable to obtain a fair trial in Holmes County, Miss., and that a change of venue was necessary, the state Supreme Court ruled June 29 (Bayer Corp. v. Mary Reed, No. 2004-IA-01968-SCT, Miss. Sup.; 2006 Miss. LEXIS 355). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Plaintiffs Defend Expert's Reliance On Adverse Event Reports In Daubert Replyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation Plaintiffs' Steering Committee (PSC) in a June 23 brief argues that the expert report of John Farquhar, M.D., in which he opines that Baycol was the most toxic statin, "adheres to the highest level of scientific methodology" and should be admitted under Daubert (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See April 2006, Page 4). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Bayer Opposes Daubert Challenge To Dr. Janet Arrowsmith-Loweemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - Bayer Corp. in a June 23 memorandum before the Baycol multidistrict litigation court, is arguing that the plaintiffs' only Daubert challenge to a defense expert should be denied because it is based on the expert's conclusion and not the qualifications of the expert or the expert's credentials (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Persistent Myopathy Opinion Supported By Literature, PSC Saysemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation Plaintiffs' Steering Committee (PSC) is arguing in a June 23 brief that the opinion of its expert Charles E. Boult, M.D., that Baycol can cause persistent myopathy is supported by the medical literature (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Expert's Testimony Based On First-Hand Experience, PSC Saysemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation Plaintiffs' Steering Committee (PSC) argues in a June 23 brief that the testimony of expert R. Samuel Mayer, M.D., is reliable because it is based on his first-hand experience with patients (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See related stories in this issue). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

PSC Points To 'Sheer Number' Of Baycol Adverse Events In Briefemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation Plaintiffs' Steering Committee (PSC) in a June 23 brief is defending their labeling of expert Dr. Stephen Raskin, arguing that his prior work for Bayer Corp. makes him qualified to offer his opinion (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See related stories in this issue). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

PSC: Medical Community Consensus Holds Baycol Most Toxic Statinemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The Baycol multidistrict litigation Plaintiffs' Steering Committee (PSC) in its June 23 brief opposing a Daubert challenge to expert Dr. David P. Richman argues that the consensus of the medical community is that Baycol is the most toxic of all statin drugs (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See related stories in this issue). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Plaintiffs Defend Viewpoints Of Toxicology Expertemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - The plaintiffs in the Baycol multidistrict litigation say in a June 23 brief that expert Martyn T. Smith, Ph.D., based his expert opinions on the toxicity of Baycol on the totality of animal and human toxicology data and that they are admissible (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Plaintiffs Argue Testimony Supporting Chronic Injury From Baycol Is Reliableemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - In a June 23 brief, the plaintiffs in the Baycol multidistrict litigation are defending the opinions of their muscle damage generic expert, Thomas M. Zizic, M.D., arguing that his opinion that Baycol can cause chronic injury is reliable under Daubert (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.; See related stories in this issue). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

MDL Plaintiffs Allowed Discovery Into Confidential Documents Disputeemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
MINNEAPOLIS - At an emergency hearing on June 12, Judge Michael J. Davis of the Baycol multidistrict litigation in the U.S. District Court of Minnesota granted a request by the lead counsel for the plaintiffs to conduct depositions regarding confidential documents allegedly coerced from a pro se litigant during deposition by a defense attorney (In Re: Baycol Products Litigation, MDL No. 1431, D. Minn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Wrongful Death Suit Filed Against AstraZeneca For Crestoremail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
NASHVILLE, Tenn. - The next of kin of a Tennessee woman on July 18 sued AstraZeneca Pharmaceuticals in federal court, arguing that the deceased died of rhabdomyolysis caused by the statin drug Crestor (Lisa R. Climer, et al. v. AstraZeneca Pharmaceuticals, LP, et al., No. 3-06-0694, M.D. Tenn.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Woman Sues AstraZeneca For Near-Fatal Rhabdo Allegedly From Crestoremail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
DENVER - A woman who allegedly suffered near-fatal rhabdomyolysis from the statin drug Crestor filed suit against the manufacturer, AstraZeneca Pharmaceuticals, in a federal court on July 14 (Madge Skinner v. AstraZeneca Pharmaceuticals, LP, et al., NO. 06-CV-01370, D. Colo.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Expert's Lipitor/AION Link Invalid Under Daubert; Summary Judgment Grantedemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
FORT WAYNE, Ind. - An Indiana federal judge on May 19 dismissed a Lipitor eye injury case after finding that the plaintiff's expert failed to meet Daubert standards for causation (Janet Bickel, et al. v. Pfizer, Inc., et al., No. 03-372, N.D. Ind., Fort Wayne Div.; 2006 U.S. Dist. LEXIS 32302). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

17 New Complaints Filed Against Pfizer For Alleged Lipitor Neuropathyemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
NEW YORK - A group of 17 plaintiffs, all claiming similar injury related to use of the popular statin drug Lipitor, sued Pfizer Inc. in the New York County Supreme Court County on July 14 (Angela M. Bibbo v. Pfizer, Inc., No. 06109836, N.Y. Sup., N.Y. Co.). Full story on lexis.com
Source: LexisNexis® Mealey's™ Baycol Legal News - July 30, 2006 Category: Medical Law Source Type: info

Frist's 11th-Hour Legislation Would Virtually Immunize Drug Makers, Public Citizen Saysemail this articleEmail this article to a colleague. save this article to My ClippingsSave this article to My Clippings. discuss this articleDiscuss or comment on this article.
WASHINGTON, D.C. - A federal law that gives drug companies virtual legal immunity in times of national health emergencies was written by a drug industry association and secretly slipped into a defense appropriations bill by Senate Majority Leader Bill Frist, R.-Tenn., according to a May 4 report by Public Citizen.
Source: LexisNexis® Mealey's™ Baycol Legal News - July 16, 2006 Category: Medical Law Source Type: info